1. 10P Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC. (15th December 2019) Authors: Mazzaschi, G; Minari, R; Ferri, V; Gnetti, L; Bersanelli, M; Cavazzoni, A; Bordi, P; Squadrilli, A; Buti, S; Cosenza, A; Ferri, L; Rapacchi, E; Petronini, P G; Missale, G; Quaini, F; Tiseo, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1404PSafety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. (23rd October 2018) Authors: Morelli, A M; Migliorino, M R; Morabito, A; Chiari, R; Grossi, F; Bordi, P; Di Costanzo, F; Delmonte, A; Romano, G; Misino, A; Scotti, V; Gregorc, V; Pisconti, S; Ceresoli, G L; Del Conte, A; Colantonio, I; Ciuffreda, L; Capelletto, E; Stura, I; Novello, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity. Issue 1 (11th December 2014) Authors: Minchom, A R; Saksornchai, K; Bhosle, J; Gunapala, R; Puglisi, M; Lu, S K; Nimako, K; Coward, J; Yu, K C; Bordi, P; Popat, S; O'Brien, M E R Journal: BMJ open respiratory research Issue: Volume 1:Issue 1(2014) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗